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Background. The correction of anemia using erythropoeitin
(EPO) is accorded high priority in the management of patients
undergoing hemodialysis (HD). Target hemoglobin (Hb) levels
have been established in many countries. Following an observa-
tion that the mean facility EPO dose in a chain of facilities in
the United States varied by more than two-fold, an examination
of the practice of anemia correction in other settings was carried
out.
Methods. We reviewed demographic and laboratory param-
eters in prevalent HD patients in 50 United States facilities
and in a single HD facility in Vicenza, Italy. The mean EPO
dose profile of the United States facilities was compared with
the profiles in 10 facilities in the eastern United Kingdom
(UKER) and in 20 facilities reporting to the United Kingdom
Renal Registry (UKRR). Analysis of the factors that correlate
with EPO resistance was carried out using the United States
and Italian data.
Results. The average EPO doses, by facility, in the 51 United
States, the 10 UKER, and the 19 UKRR facilities were 19,569,
8,416, and 7,992 international units per week (IU/wk), respec-
tively. While examination of the UKRR revealed a similar
degree of inter-facility variation (2.6-fold), much larger doses
of EPO were being administered in the United States patients,
particularly in the low Hb group. Multivariate analysis of the
United States data suggested that factors related to inflamma-
tion, including low albumin, the use of tunneled catheters for
vascular access, and low protein catabolic rate (enPCR) corre-
lated with low Hb and relative EPO resistance.
Conclusion. Despite similar guidelines for anemia manage-
ment, significant differences in practice are observed. While
there seems to be a reluctance to administer large EPO doses
to individual patients in Europe, this does not seem to apply
in the United States, where more EPO is given. EPO resistance
seems relative rather than absolute in many patients, allowing
some to respond to the higher doses.
The anemia of chronic kidney disease (CKD) has been
well characterized and the intricacies of treatment, pri-
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marily with erythropoietin (EPO) and iron, are familiar
to those caring for patients in the various stages of this
illness. Evidence-based guidelines for the management
of anemia have been developed in many countries. The
United States National Kidney Foundation DOQI guide-
lines were published in 1997 [1]. Several European coun-
tries also established their own guidelines in the mid
1990s. Recently, the European Renal Association pub-
lished the European Best Practice Guidelines (EBPG),
which addressed standards in a number of areas, includ-
ing anemia management [2]. These initiatives have been
generally successful in increasing hemoglobin (Hb) lev-
els in patients with CKD and particularly in end-stage
renal disease (ESRD) patients receiving dialysis. In the
United States, clinical performance measures on anemia
management, among other quality issues, have been in-
stituted nationwide, with clear demonstrations of im-
provement in standards of care. Several European coun-
tries have renal registries in place that effectively monitor
outcomes according to the agreed standards.
It is well known that in order to respond to EPO or
EPO analogs the patient must be replete with iron,
which, due to poor absorption and tolerance by the oral
route, is most often administered intravenously. Also,
EPO/analogs themselves can be administered by the in-
travenous route or by the subcutaneous route, the latter
often providing the opportunity for self-administration,
sometimes at home, and being slightly more economic
from the dose response aspect. As a result, practice pat-
terns can be highly variable, despite the aim toward a
common goal. It is also recognized that individual pa-
tients respond very differently, with a minority appearing
to be drug resistant. Intercurrent infection is probably
the most common reason why patients become tempo-
rarily (and reversibly) resistant, but some more chronic
conditions can have a more insidious effect. These are
well documented and include iron deficiency, real or
functional, myelofibrosis, malignancy, vitamin deficiency,
thalassaemia, sickle cell disease, and, very rarely, anti-
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bodies directed against EPO. Since patient demographic
profiles in countries with mature renal replacement ser-
vices tend not to be too dissimilar, and despite some of
the above issues, it could reasonably be presumed that
similar experiences would be reported in anemia man-
agement.
During a routine quality assurance meeting it was
noted that the mean dose of EPO per patient receiving
the drug varied widely between facilities in a chain of
53 renal centers managed by the same service provider,
The Renal Research Institute, New York (RRI). Despite
shared protocols covering a wide range of technical, psy-
chosocial, pharmaceutical, and medical care areas, the
review revealed a 2.5-fold variation in the EPO usage,
despite this being one of the most expensive components
of total therapy. Our group was aware that interfacility
comparisons had been carried out elsewhere. We felt it
would be instructive to review the comparative data that
was readily available and to explore why there were
these large interfacility differences.
METHODS
RRI (United States) sample
All patients who had been receiving HD for at least
six months prior to April 2003 and had received at least
one HD treatment and received EPO in that month in
53 Renal Research Institute–owned or managed facilities
were selected for study (N  4381). The majority of
the facilities were in New York, but some also were
in Connecticut, North Carolina, Michigan, Illinois, and
California. Demographic, disease, and therapy param-
eters recorded included age, gender, race, years on dial-
ysis, weight in kg, body mass index (BMI) (computed as
the ratio of the post-dialysis body weight to the square of
the patient’s height in meters), the presence of a tunneled
permanent catheter for vascular access, and the presence
of diabetes. The EPO doses per week (IU and IU/kg)
were recorded for the months of March 2003. Dialysis
dose was reflected in the two-pool equilibrated Kt/V
(eKt/V), where K is the clearance of urea by the dialyzer
(mL/min), t is dialysis duration, and V is the volume of
body water. Computation of the eKt/V from pre- and
post-dialysis urea measurements allowed the derivation
of the equilibrated protein catabolic rate, which was nor-
malized to the patient’s body weight (enPCR) and ex-
pressed in g/kg/day. Laboratory parameters included Hb
expressed in g/dL, albumin in g/dL, parathyroid hormone
(PTH) in pg/mL, calcium in mg/dL, phosphorus in mg/dL,
transferrin saturation (%), ferritin, total white blood cell
count (WBC), lymphocyte count, and neutrophil count
in 109/L.
Since all patients had been receiving HD for at least
six months, management of anemia should have been
past the initiation phase and ongoing in all patients. In
order to gain insight into the relative resistance to EPO,
three Hb levels were chosen for the analysis of respon-
siveness to the drug. These were Hb 10, 10 to 12, and
12 g/dL.
United Kingdom samples
A survey of EPO usage in 10 nephrology/dialysis facili-
ties in the Eastern Region of the UK National Health
Service was carried out in June 2002. Coordination of
data collection was done by Ortho-Biotech. While EPO
use was recorded in all dialysis patients, the mean dosage
of EPO in only those HD patients who had been receiv-
ing the drug for more than three months was used in
this study (N 1035). At the time of the data collection,
the United Kingdom Renal Association Standard re-
quired that 85% of all HD patients should have an Hb
10 g/dL. The European Best Practice Guidelines recom-
mended that 85% of dialysis patients should have an
Hb 11 g/dL. Patient demographic data (including
weight) was not part of the survey, and dosage was ex-
pressed as the total number of units administered per
week (IU/wk). Although not recorded, the most com-
mon route of administration of EPO in the United King-
dom at that time was subcutaneous, including the major-
ity of HD patients.
The United Kingdom Renal Registry, which receives
automated electronic download of patient data from re-
nal centers, had participation from 38 of the 63 adult
nephrology/dialysis units in England and Wales in 2002.
The December 2002 report contained data on EPO pro-
vision in 19 of these centers. The mean and median
weekly dose for those patients receiving the drug is re-
ported and expressed in IU/wk.
Italian sample
In May 2003, 105 patients undergoing regular HD in
the renal center in St. Bortolo Hospital in Vicenza, in
northeastern Italy, were receiving EPO. Demographic
and laboratory data was available which allowed some
comparative analysis with the much larger group from
the RRI in the United States. The dose of EPO could
be expressed as IU/wk or IU/kg/wk.
Analysis
Normally distributed continuous variables were char-
acterized by mean standard deviation; skewed contin-
uous variables were characterized by the median, mini-
mum, and maximum, and categorical variables were
characterized by frequency/total and expressed as a per-
cent. Severity of EPO resistance was defined as either
EPO dose/Hb or by EPO dose /(weightHb). A natural
log transformation was applied to normalize skewed vari-
ables in order to use them in parametric analyses. Uni-
variate analyses to determine possible predictors of EPO
resistance were done using either Pearson correlations
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Fig. 1. Distribution of the mean erythropoei-
tin (EPO) doses (IU/wk) in 50 Renal Research
Institute facilities.
in the case of continuous covariables (e.g., age, log ferri-
tin), or the Student t test in the case of categorical pre-
dictors (e.g., gender). Multiple regression with fixed en-
try was used to test for the strength of correlation
between each predictor controlling for all other pre-
dictors. In addition, patients with severe anemia were
defined as patients with Hb10 g/dL and receiver opera-
tor characteristics (ROC) analysis was used to determine
the optimal cut-off for predicting severe anemia based
on EPO dose. EPO-resistant patients were then defined
as patients with severe anemia who were also above the
threshold established by the ROC analysis. The t test
and the chi-square test were used to identify significant
univariate predictors of EPO resistance in the case of
continuous and categorical predictors, respectively. Lo-
gistic regression with fixed entry was used to test for the
strength of association between each predictor and EPO
resistance, controlling for all other predictors. All statis-
tical tests were done using a 0.05 level of significance.
All analyses were done using SPSS 10.1 (SPSS, Inc.,
Chicago, IL, USA).
RESULTS
Inter-facility EPO dose variation
The distribution of the mean EPO doses in 50 of the
53 RRI facilities is shown in Figure 1. The mean facility
dose, using the total number of HD patients receiving the
drug as the denominator, ranged from 11,475 to 28,932
IU/wk. There was a 2.5-fold variation around a mean
facility dose of 19,569 IU/wk. The distribution of mean
EPO doses in the 10 UKER facilities and in the 19
facilities reporting to the United Kingdom Renal Regis-
try are shown in Figure 2. The mean facility dose in the
UKER facilities ranged from 7210 to 9294 IU/wk, which
shows a 1.3-fold variation around a mean facility dose
of 8,416 IU/wk. The mean facility dose in the UKRR
facilities ranged from 4929 to 12,667 IU/wk, a 2.6-fold
variation around a mean facility dose of 7992 IU/wk.
While a larger variation of mean dose is seen in the
UKRR data compared to the UKER data, the amount
of EPO is of a similar order in the eastern region of the
United Kingdom as in England and Wales as a whole.
The distributions of facility doses in the 50 RRI and
UKRR centers are compared in Figure 3. While both
show an approximate 2.5-fold variation in dose, much
more EPO is being administered in the United States
centers.
Scatter plots of Hb and weekly EPO dose for the RRI
and UKER patients are shown in Figure 4. The left upper
quadrant illustrates the most satisfactory outcome, with
Hb in the target range at the cost of modest doses of
EPO. The poorest outcome is represented by the lower
right quadrant, which represents failure to achieve target
Hb at the expense of large doses of EPO. While it ap-
pears that more RRI patients are achieving target, it is
clear that proportionally more patients are receiving
large doses of the drug to achieve this outcome. Clearly,
it is not common practice to give large doses of EPO to
correct low Hb in the UKER. One interpretation of this
figure is that more effort (i.e., higher EPO dosing) is put
into patients who are failing to respond to moderate
doses in the United States, whereas some of these pa-
tients, who are presumably relatively EPO-resistant, re-
main below target in the United Kingdom.
Demographic and clinical characteristics related
to EPO resistance
Table 1 shows the demographic and clinical character-
istics and selected laboratory parameters in the 4381
patients in the RRI sample. Table 2 shows the univariate
associates of clinical and laboratory parameters with
EPO to Hb ratios, with and without adjustment for
weight. Almost all factors are significant, and there is a
similar pattern of results for the ratios with and without
adjustment for weight. Albumin (low), low transferrin
Greenwood et al: EPO dose variation in different facilities in different countries S-81
Fig. 2. Distribution of the mean erythropoei-
tin (EPO) doses (IU/wk) in 10 UK Eastern
Region (UKER) facilities and in 19 facilities
reporting to the UK Renal Registry.
saturation, low ferritin, and low lymphocyte count ap-
pear to have the strongest influences. Table 3 shows
a multiple regression analysis illustrating the effect of
regressing each of the measures of EPO resistance onto
their respective univariate predictors. There appear to
be three main factors among the significant multivariate
predictors. Based on inspection of the beta coefficients,
parameters that suggest the presence of inflammation
appear to be the most important, namely low albumin
and low lymphocyte count. Another class of predictors
includes a low enPCR and low phosphate, both markers
of malnutrition. Finally, there are also markers of iron
depletion, transferrin saturation, and ferritin. Catheter
use is also important. Multiple regression of the Italian
data yielded similar results. EPO resistance adjusted for
weight was significantly related to albumin (beta.31,
P  0.002), transferrin saturation (beta  .29, P 
0.002), and Kt/v (beta  .25, P  0.009). The beta
coefficients for EPO resistance not adjusted for weight
were –0.25 for albumin (P 0.009),0.30 for transferrin
saturation (P  0.002), and –0.32 for Kt/v (P  0.001).
In order to establish a possible empirical definition of
EPO resistance, we defined severe anemia as having an
Hb 10g/dL. An ROC analysis was done to determine
how well EPO dose could identify patients with Hb10/
g/dL. This yielded an area under the curve of 0.81 (P 
0.001), which indicated that EPO dose was a fairly good
predictor of severe anemia. An EPO dose of 7543 IU/
treatment (22,629 IU/wk) was found to optimize sensitiv-
ity and specificity at about 0.74.
A total of 216 patients, or 5%, were identified as EPO-
resistant by this definition. Table 4 shows the univariate
associations with resistance to EPO as defined by severe
anemia and EPO dose equal to or greater than 7543
IU/treatment. Many of these parameters had also been
significant predictors of the continuous measurement of
EPO resistance. Resistant individuals are younger, heav-
ier, have lower albumin, lower Ca  P product, lower
mean corpuscular volume (MCV), lower phosphorus,
low transferrin saturation, lower enPCR, lower lympho-
cyte count, higher neutrophil count, and higher catheter
use. Table 5 shows the results of a multivariate logistic
regression of resistance, as defined above, showing the
odds ratios of the significant factors. The three significant
factors were age, albumin, and enPCR. Similar results
were found when the weight-controlled measure of EPO
resistance was used to determine a cut-off for EPO dose
and severe anemia. The small size of the Italian group
precluded doing a similar set of analyses to look at pre-
dictors of EPO resistance in patients with Hb 10 g/dL
and high levels of EPO.
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Fig. 3. Comparison of facility mean erythro-
poeitin (EPO) doses (IU/wk) in 50 Renal Re-
search Institute (RRI) and 19 UK Renal Reg-
istry (UKRR) facilities. Percent patients with
Hb 10 g/dL was 90 and 81, respectively.
DISCUSSION
The starting point for this study was the observation
of large (2.5-fold) inter-facility differences in the con-
sumption of EPO, one of the most expensive components
of renal replacement therapy. The observation was par-
ticularly interesting in that the 53 facilities involved were
managed by a single provider, and routine quality assur-
ance along agreed guidelines and targets was accorded
high priority. Indeed, standards for the correction of
anemia have been in place for a number of years and
these are thoroughly ingrained into the clinical manage-
ment culture in these centers. Also, the intricacies of
anemia management with iron and EPO have become
better understood since EPO was first introduced into
routine clinical practice over 13 years ago. A cursory
review of facility data suggested that the observed varia-
tions could not be explained by any obvious differences
in clinical or demographic profiles. Our group thought
it would be instructive to look further to see if similar
differences existed in dialysis patients in other health
care environments. In doing this, we were aware that
most countries with mature renal replacement programs
have developed anemia management guidelines and the
European Renal Association have published Best Prac-
tice Guidelines including anemia management.
Our starting point was the United Kingdom, where
we were aware that data on anemia correction in HD
patients was available both on a regional level and
through the national renal registry (UKRR) [3]. The
comparison of parameters between different databases
is fraught with difficulties, many of which would apply to
dosages of drugs. First, the dose profile in any individual
facility is likely to be skewed and mean values have to
be interpreted with caution. Median values are likely to
be more representative. Also, taking a mean or median
among different facilities may not provide data suffi-
ciently robust to draw scientific conclusions. Further-
more, it is known that the route of administration of
EPO can affect outcome. Because of perceived economic
advantages the main route of administration in the
United Kingdom at the time of this study was subcutane-
ous; the practice in the United States was generally intra-
venous. Nonetheless, we felt that our study might be
instructive if differences were large, in which case we
might be able to draw broad conclusions. Interestingly,
the variation in dosage among 19 centers currently re-
porting to the UKRR was of a similar order to that
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Fig. 4. Scatter plot of Hb vs. weekly erythro-
poeitin (EPO) dose for the Renal Research
Institute (RRI) and UK Eastern Region pa-
tients.
Table 1. Demographic and clinical characteristics and selected
laboratory parameters of the 4381 patients in the Renal Research











Bio PTH 159.4 (4, 2787)
Phosphorus 5.41.6






WBC 6665 (1300, 65100)
Lymphocytes 22.79.0
Neutrophils 63.710.8
EPO 5000.0 (1000, 50909)
EPO/Hb ratio 420.0 (61.8, 6376.9)
EPO/(weight  Hb) 5.8 (0.48, 115.3)
Abbreviations are: BMI, body mass index; PTH, parathyroid hormone;
enPCR, equilibrated protein catabolic rate; MCV, mean corpuscular volume;
WBC, white blood cells; EPO, erythropoeitin; Hb, hemoglobin.
Table 2. Univariate associates of clinical and laboratory parameters
with EPO/Hb and EPO/(weight  Hb) ratios
Log EPO
Log EPO/Hb (weight  Hb)
Parameter (P value) (P value)
Age 0.06 (0.001)a 0.02 (0.23)
Weight kg 0.06 (0.001) NA
Albumin 0.24 (0.001) 0.27 (0.001)
Phosphorous 0.06 (0.001) 0.03 (0.04)
Ca  P 0.04 (0.006) 0.01 (0.45)
eKT/V 0.10 (0.001) 0.01 (0.69)
enPCR 0.13 (0.001) 0.11 (0.001)
Transferrin saturation 0.19 (0.001) 0.16 (0.001)
Log WBC 0.05 (0.001) 0.07 (0.001)
Lymphocytes 0.14 (0.001) 0.14 (0.001)
Neutrophil 0.10 (0.001) 0.10 (0.001)
Log ferritin 0.19 (0.001) 0.17 (0.001)
Sex 6.070.80 (0.09)b 1.860.83 (0.001)Female
Male 6.030.81 1.690.83
White 6.030.80 (0.05) 1.750.85 (0.03)Non-white
White 6.080.79 1.800.80
Catheter No 5.990.80 (0.001) 1.700.82 (0.001)
Yes 6.200.79 1.930.83
For abbreviations, see Table 1.
a Results for continuous predictors reported as Pearson correlation r (P value)
b Results for categorical predictors reported as meanSD (P value)
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Table 3. Multiple regression analysis showing the effect of
regressing each of the measures of EPO resistance onto their
respective univariate predictors
Log EPO/Hb Log EPO/Weight  Hb
Beta coefficient Beta coefficient
Parameter (P value) (P value)
Age 0.14 (0.001) NA
Weight 0.05 (0.006) NA
Albumin 0.23 (0.001) 0.21 (0.001)
Ca  P 0.07 (0.19) NA
eKT/V 0.008 (0.69) NA
Phosphorous 0.03 (0.58) 0.05 (0.01)
Transferrin saturation 0.09 (0.001) 0.06 (0.001)
enPCR 0.07 (0.001) 0.05 (0.01)
Log WBC 0.12 (0.001) 0.14 (0.001)
Lymphocytes 0.20 (0.001) 0.21 (0.001)
Neutrophil 0.04 (0.19) 0.06 (0.10)
Log ferritin 0.13 (0.001) 0.12 (0.001)
Sex 0.02 (0.29) 0.07 (0.001)
White 0.02 (0.32) 0.04 (0.05)
Catheter 0.03 (0.11) 0.03 (0.07)
For abbreviations, see Table 1.
Table 4. Univariate associations with resistance to EPO defined
by anemia (Hb 10 g/dL) and an EPO dose equal to or
greater than 7543 IU/Tx or 22,629 IU/wk
Parameter Nonresistant Resistant P value
Age 60.715.3 56.915.4 0.001
Weight 74.920.6 78.426.0 0.016
Albumin 3.90.4 3.50.6 0.001
Ca  P 50.615.3 45.315.0 0.001
eKT/V 1.40.3 1.30.3 0.001
MCV 94.17.3 91.810.0 0.001
Phosphorous 5.41.6 5.01.6 0.001
Transferrin saturation 32.814.7 27.616.4 0.001
enPCR 0.90.2 0.80.2 0.001
Lymphocytes 22.98.9 20.610.0 0.001
Neutrophils 63.4810.7 66.712.0 0.001
Catheter 129/3172 (4%) 89/1322 (6%) 0.002
For abbreviations, see Table 1.
observed in the 53 RRI–United States centers. There
was a 2.5-fold variation in the reported mean facility
dose and a 3-fold variation in the median values. Less
variation was observed among the 10 facilities in the
eastern part of the United Kingdom. However, the mean
values were closely comparable, suggesting a uniform
approach to the management of anemia correction. Also,
it is known from the Dialysis Outcomes and Practice
Patterns Study (DOPPS) [4] that the mean and median
EPO dose for a point-prevalent sample of HD patients
in Euro-Dopps who had been on dialysis for more than
90 days and who were receiving EPO therapy in the
years 1998 to 1999 was 88 IU/kg/wk. Dividing the UKRR
(2002) median EPO dose by the average weight from
one of the reporting centers (Stevenage), a comparative
figure of 86 IU/kg/wk is obtained. Although this is only a
rough assessment, it suggests that the practice of anemia
Table 5. Multivariate analysis of resistance (Hb 10 g/dL and
an EPO requirement equal to or exceeding 7543 IU/Tx or 22,629
IU/wk) showing the odds ratios of the significant factors




For abbreviations, see Table 1.
management in the United Kingdom does not differ sub-
stantially from that in other European countries.
The most striking comparison to emerge was the very
large difference in EPO usage between the United King-
dom and the RRI-United States facilities. Over twice as
much EPO seemed to be administered in the United
States to achieve roughly the same objective. The scatter
plots of Hb against EPO dose for individual patients in
the UKER and RRI-United States were revealing. They
showed a stark difference in practice, whereby EPO
doses in the United Kingdom patients are rarely above
the 250 to 300 IU/kg/wk mark. This contrasts with the
United States patients, who commonly received doses
above this, some receiving as much as 450 IU/kg/wk,
which would equate to 34,000 IU/wk. Such doses would
be rarely administered in the United Kingdom (RG,
personal communication, 2000). Doses above 30,000
IU/wk would rarely be administered in the St. Bortolo
Hospital in Vicenza, Italy. The scatter plots suggest the
higher doses are effective in correcting anemia, and a
higher percentage of RRI-United States patients had a
Hb above 10 gm/dL than the UKER patients (90% vs.
81%). Given this observation, we embarked upon a sec-
ond phase to this study, which investigated the factors
that lead to high EPO dose requirements.
Parameters that suggested the presence of inflamma-
tion appeared to be the most important determinants of
high EPO dose requirement. Most important were low
albumin and low lymphocyte count. Another class of
predictors included a low enPCR and low phosphate,
both markers of poor nutrition. Also, as might be ex-
pected markers of iron depletion, low transferrin satura-
tion and low ferritin levels came out in the analysis.
Catheter use was also important. Analysis of the Italian
data yielded similar results, EPO resistance being related
to albumin, low transferrin saturation, and low Kt/V, a
marker of under-dialysis. Relatively few catheters were
used in the Italian patients. Focusing further on EPO
resistance using ROC analysis, a dose of 7500 IU/treat-
ment or 22,500 IU/wk identified 216 patients (5%) with
low Hb as EPO resistant by this definition. Resistant
individuals were younger, had lower albumin and phos-
phorus, lower enPCR, lower lymphocyte and higher neu-
trophil counts, and higher catheter use. The three most
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Fig. 5. Receiver operator characteristics (ROC) analysis to determine
the optimal cutoff for predicting severe anemia (Hb 10 g/dL) based
on erythropoeitin (EPO) dose.
significant factors to emerge from multivariate logistic
regression were age, albumin, and enPCR.
The distribution of EPO dose across the whole Hb
range for the RRI-United States patients is plotted in
Figure 6. In this group of facilities, and consistent with
the above, very high doses of EPO are being given to
patients with Hb levels lower than 10 g/dL. What is
somewhat surprising is the stability of dose for used in
patients who have achieved Hb levels between 11 to
13.0 g/dL. Should the RRI data be representative of the
United States dialysis population, it could be argued that
there is little to support the current policy to restrict Hb
level to less then 12.5 g/dL. In support of a relaxation
is the evidence from a large observational study that
patients show no deleterious effect of having Hb 12.5
g/dL. It seems likely that more attention to the patients
with low Hb and high EPO requirement would impact
more on the economics of the whole dialysis program.
While patients with low albumin and low PCR will be
present in any RRT program, the high catheter use in the
United States is amenable to some correction through the
creation of more natural arteriovenous fistulas for vascular
access, as is seen in most European countries.
Inflammation from whatever source is of topical inter-
est as regards the holistic management of patients on
dialysis. The origin of inflammation in dialysis patients
is clearly multifactorial. The use of ultrapure water, with
minimal endotoxin content, has been associated with
lower C-reactive protein (CRP) concentrations and de-
creased EPO requirements [5]. In this study, all patients
in the RRI group were exposed to water containing less
than 0.06 EU/mL, which would not have affected EPO
resistance to any known extent. By contrast, infections
are common, particularly with use of chronic tunneled
Fig. 6. Distribution of erythropoeitin (EPO) dose across the whole Hb
range for U.S. Renal Research Institute patients.
jugular vein catheters, which were used in 29% of the
RRI patients. Catheter usage was significantly greater
in the low Hb groups.
The mechanism of impaired EPO response is likely
to be through pro-inflammatory cytokines. CRP and cy-
tokines were not measured routinely in this study but
there was a correlation between lower lymphocyte
counts and higher neutrophil counts in those patients
who were EPO resistant. The value of their measurement
as an indication of inflammation been recently reported
by Reddan et al [6]. This group highlighted the close
association of adverse cardiovascular outcomes and all-
cause mortality with increases in neutrophils, and to a
lesser extent reduction in lymphocytes. Gunnel et al [7]
defined EPO resistance by the ratio of the weekly EPO
dose to hematocrit (EPO/Hct). The best predictors of
resistance to EPO were levels of CRP, but low transferrin
levels were also predictive when albumin and CRP were
excluded from analysis. As shown also in this study is
the inhibitory effect of inflammation on erythopoeisis in
a number of diseases, including AIDS; the anemia of
rheumatoid arthritis can be overcome by large dose of
EPO [8]. Both iron deficiency and lack of reutilization
of iron from reticuloendothelid macrophages are reasons
for EPO resistance. An increase in lactoferrin receptors,
enabling them to internalize more iron, makes the latter
less available. Recently, Ganz [9] has suggested that hep-
cidin, a 25-amino acid peptide made by hepatocytes,
may be a major factor in regulating iron. Evidence from
transgenic mice expressing mRNA for hepcidin suggests
that it reduces iron absorption and iron release from
macrophages. In inflammation, hepcidin production may
increase substantially, so that it is possible that this sub-
stance plays an important role in EPO resistance.
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